XORTX Therapeutics : Investor Presentation

Redefining Kidney Disease

January 10th, 2022 Investor Presentation

:XRTX : ANU1

Forward Looking Statements

This company presentation may include "forward-looking statements." All forward-looking statements are subject to a number of risks, uncertainties and assumptions, and you should not rely upon forward-looking statements as predictions of future events. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "will," "plan," "potential," "predict," "project," "should," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Examples of forward looking statements contained in this presentation include, among others, statements regarding our ability to develop and commercialize XRx-008; our ability to develop other products in our pipeline; status, timing and results of preclinical studies and clinical trials; the potential benefits of XRx-008; the timing of seeking regulatory approval of XRx-008; our ability to obtain and maintain regulatory approval; our estimates regarding our capital requirements; our plans to develop and market XRx- 008 and the timing of our development programs; our estimates of the size of the potential markets for XRx- 008; sources of cash, including the proceeds from this equity issuance and contributions from other sources; the rate and degree of market acceptance of XRx-008; our intellectual property position; our ability to maintain and protect our intellectual property rights; our results of operations, financial condition, liquidity, prospects, and growth strategies; our spending of the proceeds from this offering; the industry in which we operate; and the trends that may affect the industry or us. This presentation discusses product candidates that are under pre-clinical study and clinical trial and that have not yet been approved for marketing by the Food and Drug Administration. No representation is made as to the safety or efficacy of these product candidates for the therapeutic use for which they are being studied. All forward-looking statements are based upon current estimates and expectations about future events and financial and other trends. There is no guarantee that future results, performance or events reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

2

Our Mission

Developing Novel Therapies to

Address the Treatment Needs of

Patients with ADPKD and Kidney

Disease Associated with COVID-19

3

Investment Summary

 The global end stage renal disease market was valued at USD 74.5 billion in 2020 and is expected to

expand at a compound annual growth rate (CAGR) of 12.7% from 2021 to 2028 (1).

 Developing drug-based therapies for serious progressive kidney diseases with a high unmet medical

need, including ADPKD, T2DN and AKI due to COVID-19.

 Three patent families are based upon small molecules and derived from our proprietary pipeline-in-

a-producttechnology with broad therapeutic claims. Multiple studies characterizing the mechanism of action (MoA) in over 700 patients treated, including multiple Ph2 studies allowing to start of Ph3 registration trials;

for Autosomal Dominant Polycystic Kidney Disease	AKI due to Coronavirus infection/	for type 2 Diabetic Nephropathy (T2DN >
(ADPKD > 140 k patients in the US) where there are	COVID-19 (WW Pandemic)	12 m patients in the US)
very limited treatment options and expected to initiate
Ph3 pivotal registration clinical trial within 12 months

 Senior team was responsible for Oxypurinol development in prior ventures and our key opinion leader -
Dr. Richard J. Johnson Jr., MD, a globally recognized kidney researcher, professor, Nephrologist at the University
of Colorado School of Medicine. Management team satisfies new diversity "matrix".
Source:(1) End Stage Renal Disease Market Size, Jan 2021, GVR	4

First-in-Class Uric Acid Lowering Agent in Late Stage Ph3 Clinical Trials in ADPKD

XORTX Therapeutics Inc. Pipeline

XORTX Therapeutics holds US, EU and other national rights for all programs

Therapeutic	Disease	Pre-clinical	Phase I	Phase II	Phase III	Approval
	Polycystic		505(b)2
	Kidney Disease

Coronavirus /	505(b)2
COVID-19

Diabetic

Nephropathy

5